News & Updates

Use of colchicine provides a good balance between benefit and risk in patients with cutaneous polyarteritis nodosa without peripheral sensory neuropathy, reports a study. In the event of relapse, the best treatment appears to be the combination of glucocorticoids and azathioprine.

Use of stimulants remains high among patients with psychocutaneous disease, most of whom have one or more psychiatric comorbidity, results of a recent study have shown.

The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.

Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.

Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.